osteoarthritis model
Inflammation Models
Osteoarthritis Model
Osteoarthritis (OA) is the most common type of arthritis occurring when the cartilage between bones becomes damaged after a sustained inflammatory response, causing joints to become painful, swollen and hard to move. Pain, reduced mobility and adverse effects from medications substantially affect the patient quality of life. Cellomatics offers OA in vitro models which recapitulate the main disease phenotypes: inflammation, anabolism or hypertrophy and general degradation of chodrocytes.
Available formats
Standard 96-well format.
Alternative format offerings available upon request.
Pilot assay development is available as a standalone service, or as a built in checkpoint for full studies
Osteoarthritis Model - Frequently asked questions
Osteoarthritis models are used to study joint degeneration and inflammatory processes under controlled laboratory conditions. These systems help researchers investigate cartilage damage, disease progression, and cellular responses associated with osteoarthritis.
These models support the evaluation of potential therapies targeting inflammation, cartilage degradation, and joint dysfunction. They are widely used for target validation, mechanistic studies, and preclinical testing of new therapeutic approaches.
Researchers use a range of in vitro models, including primary chondrocytes, synoviocytes, and co-culture systems, to investigate cartilage breakdown, inflammatory signalling, and tissue remodelling associated with osteoarthritis. These systems also support therapeutic screening and mechanistic research.
Common biomarkers include inflammatory cytokines, cartilage degradation/anabolic markers, and proteins associated with joint damage and extracellular matrix remodelling. These readouts help assess disease progression and therapeutic response in preclinical studies
Osteoarthritis models provide reproducible platforms to evaluate disease activity and potential therapeutic strategies in a preclinical setting. They enable biotechnology and pharmaceutical teams to investigate novel therapeutic approaches more efficiently and support informed decision-making to help de-risk drug discovery programmes prior to clinical development